Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. - Researchers sought to investigate the utility and safety of Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. A phase 3, open-label, multicenter, noninferiority trial was designed to include individuals who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy, they randomized individuals in a 1:1 ratio to either continue their oral therapy or switch to monthly intramuscular injections of long-acting cabotegravir, an HIV-1 integrase strand transfer inhibitor and long-acting rilpivirine, a nonnucleoside reverse-transcriptase inhibitor. The primary outcome included the percentage of individuals with an HIV-1 RNA level of 50 copies per milliliter or higher at week 48, determined with the use of the Food and Drug Administration snapshot algorithm.